hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Identifieur interne : 001242 ( Istex/Corpus ); précédent : 001241; suivant : 001243hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Auteurs : Else M. Inderberg Suso ; Svein Dueland ; Anne-Marie Rasmussen ; Turid Vetrhus ; Steinar Aamdal ; Gunnar Kvalheim ; Gustav GaudernackSource :
- Cancer Immunology, Immunotherapy [ 0340-7004 ] ; 2011-06-01.
English descriptors
Abstract
Abstract: Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.
Url:
DOI: 10.1007/s00262-011-0991-9
Links to Exploration step
ISTEX:542B40291AD1D244B13795B4C2BF683594DDA577Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title><author><name sortKey="Suso, Else M Inderberg" sort="Suso, Else M Inderberg" uniqKey="Suso E" first="Else M. Inderberg" last="Suso">Else M. Inderberg Suso</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Dueland, Svein" sort="Dueland, Svein" uniqKey="Dueland S" first="Svein" last="Dueland">Svein Dueland</name><affiliation><mods:affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Rasmussen, Anne Marie" sort="Rasmussen, Anne Marie" uniqKey="Rasmussen A" first="Anne-Marie" last="Rasmussen">Anne-Marie Rasmussen</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Vetrhus, Turid" sort="Vetrhus, Turid" uniqKey="Vetrhus T" first="Turid" last="Vetrhus">Turid Vetrhus</name><affiliation><mods:affiliation>Department of Radiology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Aamdal, Steinar" sort="Aamdal, Steinar" uniqKey="Aamdal S" first="Steinar" last="Aamdal">Steinar Aamdal</name><affiliation><mods:affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Kvalheim, Gunnar" sort="Kvalheim, Gunnar" uniqKey="Kvalheim G" first="Gunnar" last="Kvalheim">Gunnar Kvalheim</name><affiliation><mods:affiliation>Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Gaudernack, Gustav" sort="Gaudernack, Gustav" uniqKey="Gaudernack G" first="Gustav" last="Gaudernack">Gustav Gaudernack</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: gustav.gaudernack@rr-research.no</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:542B40291AD1D244B13795B4C2BF683594DDA577</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s00262-011-0991-9</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001242</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001242</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title><author><name sortKey="Suso, Else M Inderberg" sort="Suso, Else M Inderberg" uniqKey="Suso E" first="Else M. Inderberg" last="Suso">Else M. Inderberg Suso</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Dueland, Svein" sort="Dueland, Svein" uniqKey="Dueland S" first="Svein" last="Dueland">Svein Dueland</name><affiliation><mods:affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Rasmussen, Anne Marie" sort="Rasmussen, Anne Marie" uniqKey="Rasmussen A" first="Anne-Marie" last="Rasmussen">Anne-Marie Rasmussen</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Vetrhus, Turid" sort="Vetrhus, Turid" uniqKey="Vetrhus T" first="Turid" last="Vetrhus">Turid Vetrhus</name><affiliation><mods:affiliation>Department of Radiology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Aamdal, Steinar" sort="Aamdal, Steinar" uniqKey="Aamdal S" first="Steinar" last="Aamdal">Steinar Aamdal</name><affiliation><mods:affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Kvalheim, Gunnar" sort="Kvalheim, Gunnar" uniqKey="Kvalheim G" first="Gunnar" last="Kvalheim">Gunnar Kvalheim</name><affiliation><mods:affiliation>Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Gaudernack, Gustav" sort="Gaudernack, Gustav" uniqKey="Gaudernack G" first="Gustav" last="Gaudernack">Gustav Gaudernack</name><affiliation><mods:affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: gustav.gaudernack@rr-research.no</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Cancer Immunology, Immunotherapy</title><title level="j" type="abbrev">Cancer Immunol Immunother</title><idno type="ISSN">0340-7004</idno><idno type="eISSN">1432-0851</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2011-06-01">2011-06-01</date><biblScope unit="volume">60</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="809">809</biblScope><biblScope unit="page" to="818">818</biblScope></imprint><idno type="ISSN">0340-7004</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-7004</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dendritic cell vaccination</term><term>Epitope identification</term><term>Pancreas cancer</term><term>Telomerase (hTERT)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Else M. Inderberg Suso</name><affiliations><json:string>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Svein Dueland</name><affiliations><json:string>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Anne-Marie Rasmussen</name><affiliations><json:string>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Turid Vetrhus</name><affiliations><json:string>Department of Radiology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Steinar Aamdal</name><affiliations><json:string>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Gunnar Kvalheim</name><affiliations><json:string>Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Gustav Gaudernack</name><affiliations><json:string>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</json:string><json:string>E-mail: gustav.gaudernack@rr-research.no</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Telomerase (hTERT)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Epitope identification</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dendritic cell vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pancreas cancer</value></json:item></subject><articleId><json:string>991</json:string><json:string>s00262-011-0991-9</json:string></articleId><arkIstex>ark:/67375/VQC-DSBJ3TBG-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.</abstract><qualityIndicators><refBibsNative>false</refBibsNative><abstractWordCount>240</abstractWordCount><abstractCharCount>1690</abstractCharCount><keywordCount>4</keywordCount><score>9.868</score><pdfWordCount>4988</pdfWordCount><pdfCharCount>33167</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize></qualityIndicators><title>hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title><genre><json:string>research-article</json:string></genre><host><title>Cancer Immunology, Immunotherapy</title><language><json:string>unknown</json:string></language><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><issn><json:string>0340-7004</json:string></issn><eissn><json:string>1432-0851</json:string></eissn><journalId><json:string>262</json:string></journalId><volume>60</volume><issue>6</issue><pages><first>809</first><last>818</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Immunology</value></json:item><json:item><value>Cancer Research</value></json:item><json:item><value>Oncology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-DSBJ3TBG-3</json:string></ark><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1007/s00262-011-0991-9</json:string></doi><id>542B40291AD1D244B13795B4C2BF683594DDA577</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><licence><p>The Author(s), 2011</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2010-11-19</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title><author xml:id="author-0000"><persName><forename type="first">Else</forename><surname>Suso</surname></persName><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Svein</forename><surname>Dueland</surname></persName><affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Anne-Marie</forename><surname>Rasmussen</surname></persName><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Turid</forename><surname>Vetrhus</surname></persName><affiliation>Department of Radiology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Steinar</forename><surname>Aamdal</surname></persName><affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Gunnar</forename><surname>Kvalheim</surname></persName><affiliation>Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation></author><author xml:id="author-0006" corresp="yes"><persName><forename type="first">Gustav</forename><surname>Gaudernack</surname></persName><email>gustav.gaudernack@rr-research.no</email><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation></author><idno type="istex">542B40291AD1D244B13795B4C2BF683594DDA577</idno><idno type="ark">ark:/67375/VQC-DSBJ3TBG-3</idno><idno type="DOI">10.1007/s00262-011-0991-9</idno><idno type="article-id">991</idno><idno type="article-id">s00262-011-0991-9</idno></analytic><monogr><title level="j">Cancer Immunology, Immunotherapy</title><title level="j" type="abbrev">Cancer Immunol Immunother</title><idno type="pISSN">0340-7004</idno><idno type="eISSN">1432-0851</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">14</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2011-06-01"></date><biblScope unit="volume">60</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="809">809</biblScope><biblScope unit="page" to="818">818</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010-11-19</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Telomerase (hTERT)</term></item><item><term>Epitope identification</term></item><item><term>Dendritic cell vaccination</term></item><item><term>Pancreas cancer</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Immunology</term></item><item><term>Cancer Research</term></item><item><term>Oncology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-11-19">Created</change><change when="2011-06-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="NonStandardArchiveJournal" NumberingStyle="Unnumbered"><JournalID>262</JournalID><JournalPrintISSN>0340-7004</JournalPrintISSN><JournalElectronicISSN>1432-0851</JournalElectronicISSN><JournalTitle>Cancer Immunology, Immunotherapy</JournalTitle><JournalAbbreviatedTitle>Cancer Immunol Immunother</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Immunology</JournalSubject><JournalSubject Type="Secondary">Cancer Research </JournalSubject><JournalSubject Type="Secondary">Oncology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>60</VolumeIDStart><VolumeIDEnd>60</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd><IssueArticleCount>14</IssueArticleCount><IssueHistory><OnlineDate><Year>2011</Year><Month>5</Month><Day>21</Day></OnlineDate><PrintDate><Year>2011</Year><Month>5</Month><Day>20</Day></PrintDate><CoverDate><Year>2011</Year><Month>6</Month></CoverDate><PricelistYear>2011</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s00262-011-0991-9" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>991</ArticleID><ArticleDOI>10.1007/s00262-011-0991-9</ArticleDOI><ArticleSequenceNumber>5</ArticleSequenceNumber><ArticleTitle Language="En" OutputMedium="All">hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</ArticleTitle><ArticleCategory>Original article</ArticleCategory><ArticleFirstPage>809</ArticleFirstPage><ArticleLastPage>818</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2011</Year><Month>2</Month><Day>10</Day></RegistrationDate><Received><Year>2010</Year><Month>11</Month><Day>19</Day></Received><Accepted><Year>2011</Year><Month>2</Month><Day>8</Day></Accepted><OnlineDate><Year>2011</Year><Month>3</Month><Day>2</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>The Author(s)</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></ArticleCopyright><ArticleGrants Type="OpenChoice"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="OpenAccess"></BodyPDFGrant><BodyHTMLGrant Grant="OpenAccess"></BodyHTMLGrant><BibliographyGrant Grant="OpenAccess"></BibliographyGrant><ESMGrant Grant="OpenAccess"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Else</GivenName><GivenName>M.</GivenName><GivenName>Inderberg</GivenName><FamilyName>Suso</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Svein</GivenName><FamilyName>Dueland</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Anne-Marie</GivenName><FamilyName>Rasmussen</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Turid</GivenName><FamilyName>Vetrhus</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Steinar</GivenName><FamilyName>Aamdal</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Gunnar</GivenName><FamilyName>Kvalheim</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Gustav</GivenName><FamilyName>Gaudernack</FamilyName></AuthorName><Contact><Phone>+47-22-781326</Phone><Fax>+47-22-781345</Fax><Email>gustav.gaudernack@rr-research.no</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Section for Immunology</OrgDivision><OrgName>Oslo University Hospital and University of Oslo</OrgName><OrgAddress><Street>Radiumhospitalet, Montebello</Street><Postcode>0310</Postcode><City>Oslo</City><Country Code="NO">Norway</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Department of Clinical Cancer Research</OrgDivision><OrgName>Oslo University Hospital</OrgName><OrgAddress><Street>Radiumhospitalet</Street><City>Oslo</City><Country Code="NO">Norway</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Department of Radiology</OrgDivision><OrgName>Oslo University Hospital</OrgName><OrgAddress><Street>Radiumhospitalet</Street><City>Oslo</City><Country Code="NO">Norway</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgDivision>Department of Cellular Therapy</OrgDivision><OrgName>Oslo University Hospital</OrgName><OrgAddress><Street>Radiumhospitalet</Street><City>Oslo</City><Country Code="NO">Norway</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Telomerase (hTERT)</Keyword><Keyword>Epitope identification</Keyword><Keyword>Dendritic cell vaccination</Keyword><Keyword>Pancreas cancer</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title></titleInfo><name type="personal"><namePart type="given">Else</namePart><namePart type="given">M.</namePart><namePart type="given">Inderberg</namePart><namePart type="family">Suso</namePart><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Svein</namePart><namePart type="family">Dueland</namePart><affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne-Marie</namePart><namePart type="family">Rasmussen</namePart><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Turid</namePart><namePart type="family">Vetrhus</namePart><affiliation>Department of Radiology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steinar</namePart><namePart type="family">Aamdal</namePart><affiliation>Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gunnar</namePart><namePart type="family">Kvalheim</namePart><affiliation>Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Gustav</namePart><namePart type="family">Gaudernack</namePart><affiliation>Section for Immunology, Oslo University Hospital and University of Oslo, Radiumhospitalet, Montebello, 0310, Oslo, Norway</affiliation><affiliation>E-mail: gustav.gaudernack@rr-research.no</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">2010-11-19</dateCreated><dateIssued encoding="w3cdtf">2011-06-01</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) transfected with hTERT mRNA has the potential to induce strong immune responses to multiple hTERT epitopes and is therefore an attractive approach to more potent immunotherapy. Blood samples from such patients provide an opportunity for identification of new, in vivo processed T-cell epitopes that may be clinically relevant. A 62-year-old female patient underwent radical surgery for a pancreatic adenocarcinoma. After relapse, she obtained stable disease on gemcitabine treatment. Due to severe neutropenia, the chemotherapy was terminated. The patient has subsequently been treated with autologous DCs loaded with hTERT mRNA for 3 years. Immunomonitoring was performed at regular intervals following start of vaccination and clinical outcome measured by CT and PET/CT evaluation. The patient developed an immune response against several hTERT-derived Th and CTL epitopes. She presently shows no evidence of active disease based on PET/CT scans. No serious adverse events were experienced and the patient continues to receive regular booster injections. We here provide evidence for the induction of hTERT-specific immune responses following vaccination of a pancreas cancer patient with DCs loaded with hTERT mRNA. These responses are associated with complete remission. A thorough analysis of this patient immune response has provided a unique opportunity to identify novel epitopes, associated with clinical effects. These will be included in future hTERT vaccines.</abstract><note>Original article</note><subject lang="en"><genre>Keywords</genre><topic>Telomerase (hTERT)</topic><topic>Epitope identification</topic><topic>Dendritic cell vaccination</topic><topic>Pancreas cancer</topic></subject><relatedItem type="host"><titleInfo><title>Cancer Immunology, Immunotherapy</title></titleInfo><titleInfo type="abbreviated"><title>Cancer Immunol Immunother</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2011-05-21</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Immunology</topic><topic>Cancer Research</topic><topic>Oncology</topic></subject><identifier type="ISSN">0340-7004</identifier><identifier type="eISSN">1432-0851</identifier><identifier type="JournalID">262</identifier><identifier type="IssueArticleCount">14</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2011</date><detail type="volume"><number>60</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="pages"><start>809</start><end>818</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 2011</recordOrigin></recordInfo></relatedItem><identifier type="istex">542B40291AD1D244B13795B4C2BF683594DDA577</identifier><identifier type="ark">ark:/67375/VQC-DSBJ3TBG-3</identifier><identifier type="DOI">10.1007/s00262-011-0991-9</identifier><identifier type="ArticleID">991</identifier><identifier type="ArticleID">s00262-011-0991-9</identifier><accessCondition type="use and reproduction" contentType="copyright">The Author(s), 2011</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>The Author(s), 2011</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-DSBJ3TBG-3/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001242 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001242 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:542B40291AD1D244B13795B4C2BF683594DDA577
|texte= hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
}}
| This area was generated with Dilib version V0.6.33. |  |